News

The company is set to launch a multicentre Phase I trial in the US in the first quarter of this year. Axcynsis Therapeutics CEO Dr Zou Bin said:

BAFIERTAM will join TASCENSO ODT (fingolimod), Cycle’s other branded MS treatment. Both these therapies will be supported by Cycle’s hub programme, Cycle Vita. The company noted that, during

This designation is for Carteyva, an anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy, as a second-line treatment for adults with this disease. It is developed independently

SPRIM Global Investments and William Taylor Nominees jointly led the funding round, which will support the conduct of a Phase I trial of RheumaGen’s lead candidate, RG0401. Anticipated

PVT401 is said to be the second autoimmune drug candidate from Parvus. Parvus is focused on developing peptide-major histocompatibility complex (pMHC) nanomedicine drugs. These assets can activate in

The decision is intended for individuals with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), as assessed by an FDA-approved test. This marks offering a new

The ‘fully human’, immunoglobulin G4 (IgG4) antibody is tailored to target Protein S, aiming to restore balance in blood clotting and potentially serves as a ‘universal haemostatic therapy’

This marks the first NMPA-approved monoclonal antibody that targets gastric tumour cells expressing the biomarker CLDN18.2. The approval offers a new, highly targeted treatment option for individuals particularly

This decision follows the positive outcomes from the multicentre, open-label Phase II TRUST-I trial. The single-arm trial was instrumental in assessing the therapy’s tolerability, efficiency, and safety in